<DOC>
	<DOCNO>NCT02226926</DOCNO>
	<brief_summary>Investigation mechanism dipyridamole action platelet in-vivo study healthy volunteer treat Aggrenox comparison volunteer treat Persantin Retard Acetylsalicylic Acid use platelet Vasodilator-Stimulated-Phosphoprotein ( VASP ) -phosphorylation indication action measurement dipyridamole plasma level</brief_summary>
	<brief_title>Mechanism Dipyridamole Action Platelets : Vivo Study With Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Dipyridamole</mesh_term>
	<mesh_term>Aspirin , Dipyridamole Drug Combination</mesh_term>
	<criteria>Healthy females/males Age range 18 60 Volunteers give write informed consent accordance local ethic committee local legislation Known gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Diseases nervous system ( epilepsy ) psychiatric disorder neurological disorder Known history orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator Drug intake long halflife ( &gt; 24 hour ) , &lt; 1 month prior administration trial Volunteers receive drug might influence result trial , &lt; 10 day prior administration trial Participation another study investigational drug , &lt; 1 month prior administration trial Smoking 15 cigarette 4 cigar 4 pipes/day Drinking 60 g alcohol per day Unable refrain excessive consumption methylxanthine contain drink food Drug addiction Blood donation ( &gt; 400 ml ) , &lt; 4 week prior administration trial Participation excessive physical activity , &lt; 5 day prior administration trial For female volunteer : Pregnancy Positive pregnancy test No adequate contraception ( acceptable : oral contraceptive , condom , etc . ) Lactation period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>